Behavioural PharmacologyPub Date : 2025-10-01Epub Date: 2025-08-21DOI: 10.1097/FBP.0000000000000850
Stephen W White, Tara D Clover, Kenneth J Sufka
{"title":"Synbiotic diet produces antidepressant-like effects but alters ketamine activity in an avian model of treatment-resistant depression.","authors":"Stephen W White, Tara D Clover, Kenneth J Sufka","doi":"10.1097/FBP.0000000000000850","DOIUrl":"10.1097/FBP.0000000000000850","url":null,"abstract":"<p><p>Pre- and probiotics promote a diverse and functional gut microbiota and have demonstrated both anxiolytic and antidepressant effects; however, how synbiotic diet interacts with antidepressant medications has not been fully investigated. This study sought to evaluate the potential anxiolytic or antidepressant effects of a synbiotic diet in an avian model that presents homologies with treatment-resistant depression. In addition, we sought to evaluate the potential interaction of a synbiotic diet combined with select doses of ketamine. Socially raised Black Australorp chicks were given either standard or synbiotic feed for 7 days. At 7 days posthatch, chicks from each feed condition were administered either 0, 5, or 10 mg/kg/ml ketamine 15 min before a 90-min isolation stressor, which elicits distress vocalizations (DVocs) that temporally represent a panic-like phase followed by a depression-like phase. Saline-treated chicks given the synbiotic diet displayed significantly higher DVoc rates in the depression-like phase compared with saline-treated animals in the standard feed condition, indicative of attenuation of behavioral despair [F(1,22) = 5.45, P < 0.05]. Similarly, in the standard diet condition, ketamine 10 mg/kg produced elevated DVoc rates; however, under the synbiotic diet, both doses of ketamine produced a suppression of DVoc rates in the depression-like phase. These findings suggest that a synbiotic diet produces antidepressant-like effects in the model and a possible negative interaction between synbiotics and ketamine. While preliminary, the findings suggest the concurrent use of pre- and probiotic supplements and ketamine may produce contradictory effects and warrant further investigation.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":"36 7","pages":"526-533"},"PeriodicalIF":1.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The effect of lithium on behavioral functions in adolescent rats exposed to chronic unpredictable mild stress with respect to brain-derived neurotrophic factor and glycogen synthase kinase-3 beta levels in the prefrontal cortex.","authors":"Maryam Abbasi Mehmandost Sofla, Mahdie Gholami, Salar Vaseghi, Nooshin Barikrow, Batool Ghorbani-Yekta","doi":"10.1097/FBP.0000000000000842","DOIUrl":"10.1097/FBP.0000000000000842","url":null,"abstract":"<p><p>Chronic unpredictable mild stress (CUMS) is widely used as a reliable method to induce depressive states and anhedonia in rodents. Lithium is one of the well-known drugs used for the alleviation of symptoms in different neuropsychiatric disorders such as depression and bipolar disorder. In this research, we evaluated the efficacy of several doses of lithium on behavioral changes induced by CUMS. Also, the expression level of brain-derived neurotrophic factor (BDNF) and glycogen synthase kinase-3 beta (GSK-3beta) in the prefrontal cortex was evaluated. CUMS was done using various unpredictable stressors for 14 days. Lithium was injected at the doses of 10, 30, and 50 mg/kg. Locomotor activity, anxiety-like behavior, pain perception, and depressive-like behavior were assessed using the open field test, the novelty-suppressed feeding test, the hot plate test, and the forced swim test, respectively. The results revealed that CUMS decreased locomotor activity, increased anxiety- and depressive-like behaviors, increased pain threshold, decreased climbing, decreased BDNF level, and increased GSK-3beta level in the prefrontal cortex. However, lithium dose-dependently restored all these effects. In control rats, lithium (50 mg/kg) decreased locomotion and GSK-3beta expression levels. In conclusion, the results suggested that deleterious effects of CUMS may be mediated via BDNF and GSK-3beta in the prefrontal cortex, and lithium via suppressing GSK-3beta and upregulating BDNF expression levels in the prefrontal cortex can restore CUMS effects.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":" ","pages":"471-483"},"PeriodicalIF":1.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Behavioural PharmacologyPub Date : 2025-10-01Epub Date: 2025-08-15DOI: 10.1097/FBP.0000000000000847
Adam L Crane, Laurence E A Feyten, Alix J P Brusseau, Félixe Dumaresq Synnott, Indar W Ramnarine, Maud C O Ferrari, Grant E Brown
{"title":"Anxiolytic effects of diazepam in Trinidadian guppies exposed to chemical cues indicating predation risk.","authors":"Adam L Crane, Laurence E A Feyten, Alix J P Brusseau, Félixe Dumaresq Synnott, Indar W Ramnarine, Maud C O Ferrari, Grant E Brown","doi":"10.1097/FBP.0000000000000847","DOIUrl":"10.1097/FBP.0000000000000847","url":null,"abstract":"<p><p>The fear of predation is pervasive among vertebrate prey species, being characterized by neurobiological and behavioral changes induced by risk exposure. To understand the acquisition and attenuation of fearful phenotypes, such as dimensions of posttraumatic stress, researchers often use animal models, with prey fishes recently emerging as a nontraditional but promising model. Much is known about fear acquisition in prey fishes such as the Trinidadian guppy, Poecilia reticulata, which inhabit high and low predation sites. Little is known, however, about whether a guppy model shows fear attenuation via therapeutic treatments, such as commonly prescribed anxiolytic drugs, like benzodiazepines. In this study, we used Trinidadian guppies from wild populations to explore the interactive effects of exposure to the anxiolytic drug, diazepam, and exposure to predation risk in the form of injured conspecific cues (i.e. alarm cues) that reliably indicate a predator attack. In Experiment 1, juvenile guppies from both high- and low-predation populations were given a 10-min exposure to diazepam (160 µg/l), resulting in the loss of fear behavior when simultaneously presented with alarm cues. In Experiment 2, we found that a prior 10-min exposure to diazepam (160 µg/l) for adult guppies significantly reduced their subsequent fear behavior toward a separate exposure to alarm cues, revealing that diazepam was having direct effects on guppy cognition rather than simply inactivating the alarm cues via chemical alteration. These anxiolytic effects thus add to the growing support for the predictive validity of prey fishes as animal models for exploring fear attenuation in humans.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":"36 7","pages":"500-508"},"PeriodicalIF":1.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Haloperidol potentates the antinociceptive effect of buprenorphine and tramadol in rats.","authors":"Rolffy Ortiz-Andrade, Lilian Dolores Chel-Guerrero, Myrna Déciga-Campos","doi":"10.1097/FBP.0000000000000852","DOIUrl":"10.1097/FBP.0000000000000852","url":null,"abstract":"<p><p>This study aimed to evaluate the pharmacological effects of haloperidol on the antinociceptive effects of buprenorphine and tramadol in rats. Dose-response curves were constructed for the individual administration of haloperidol, buprenorphine, and tramadol in rats subjected to the formalin (1%) test. All the compounds demonstrated dose-dependent antinociceptive effects when administered individually. Pharmacological interactions were assessed using an isobolographic method. The doses required to achieve 50% of the maximal antinociceptive effect (ED50) for each drug were combined at a fixed 1 : 1 ratio to establish a combination series of haloperidol + buprenorphine and haloperidol + tramadol. The results showed that buprenorphine achieved a higher maximal antinociceptive effect (98%) compared with tramadol (85%) and haloperidol (84.9%) when administered individually. Isobolographic analysis revealed that the experimental values (Zexp) for haloperidol + buprenorphine (Zadd = 27.6 ± 5.5 vs. Zexp = 5.47 ± 1.2) and haloperidol + tramadol (Zadd = 4987.68 ± 651.5 vs. Zexp = 1678.23 ± 89.8) were significantly lower than the theoretical values (Zadd), indicating synergistic interactions. On the basis of the experimental data, haloperidol potentiated the antinociception in the following order: haloperidol + buprenorphine, followed by haloperidol + tramadol. These findings suggest that such drug combinations could have potential applications in the ongoing research of treatments for chronic pain, depression-related pain, and cancer-associated pain.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":"36 7","pages":"517-525"},"PeriodicalIF":1.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Interaction effect of lithium and crocin on memory performance and behavioral functions in rats exposed to chronic unpredictable mild stress.","authors":"Delaram Khastoo, Fatemeh Jafari, Batool Ghorbani Yekta, Mahsa Ale-Ebrahim, Soheila Fazli-Tabaei, Salar Vaseghi","doi":"10.1097/FBP.0000000000000848","DOIUrl":"https://doi.org/10.1097/FBP.0000000000000848","url":null,"abstract":"<p><p>Chronic unpredictable mild stress (CUMS) is an approved method for the induction of depression in rodents. Lithium, as one of the oldest psychiatric drugs, can induce beneficial effects on mood state under stressful conditions. On the other hand, crocin (active component of Saffron) has antioxidant, procognitive, and mood-enhancer effects. In this study, we aimed to investigate the interaction effect of lithium and crocin on mood disturbances and cognitive impairments induced by CUMS. CUMS was performed for 3 weeks. Lithium (100 mg/kg, i.p.), or crocin (30 mg/kg, i.p.), or combination of both was injected during CUMS period (21 injections). Open field test, hot plate, forced swimming test, shuttle box, and Morris water maze were used to evaluate locomotor activity, pain perception, depressive-like behavior, passive avoidance memory, and spatial memory, respectively. The results showed that lithium decreased locomotion and climbing, increased pain threshold and immobility, and impaired passive avoidance and spatial memory in control rats. CUMS also showed all these effects, with more intensity. However, lithium partly reversed the effect of CUMS on locomotion and spatial memory, and completely restored the effect of CUMS on immobility and passive avoidance memory. Also, lithium did not change the effect of CUMS on pain threshold and climbing. Crocin alone, and in combination with lithium significantly reversed all the effects of CUMS. In conclusion, for the first time, the results of the present research showed that the combination of lithium and crocin leads to stronger therapeutic effects on mood disturbances and cognitive impairments induced by chronic stress.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":"36 7","pages":"484-499"},"PeriodicalIF":1.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prevention of morphine dependence with a combination of ketotifen and l-carnitine in mice: a new potential therapeutic approach.","authors":"Bohloul Habibi Asl, Solmaz Fallahi, Sanam Bohlouli, Hamid Soltani Zangbar, Tahereh Eteraf-Oskouei","doi":"10.1097/FBP.0000000000000849","DOIUrl":"10.1097/FBP.0000000000000849","url":null,"abstract":"<p><p>Morphine dependence is a complex clinical issue, coinciding with oxidative stress and increased neurotransmitter levels as key factors in this drug's reliance and tolerance. This study examines how l-carnitine, ketotifen, and their combination prevent and treat morphine dependence in mice. Seventy-two male mice (20-25 g) were randomly divided into nine groups. The morphine group received morphine (50 mg/kg/i.p.) for 4 days, while the control group was given saline (10 ml/kg/i.p.). After the morphine administration, three groups received l-carnitine at doses of 25, 50, and 75 mg/kg/i.p., and the following three groups received ketotifen at doses of 4, 8, and 16 mg/kg/i.p. The final group was treated with l-carnitine (25 mg/kg/i.p.) and ketotifen (4 mg/kg/i.p.) after the morphine administration. The morphine dependence was assessed using the jumping and standing on feet indices in the naloxone test. Oxidative stress was evaluated through total antioxidant capacity (TAC) and malondialdehyde (MDA) biomarkers in blood samples. l-carnitine (25, 50, and 75 mg/kg) and ketotifen (4, 8, and 16 mg/kg) reduced the naloxone jumping index. l-carnitine (50 mg/kg) and ketotifen (8 and 16 mg/kg) reduced the standing on feet index. In addition, combining these two medications at modest doses decreased behavioral indices. All three l-carnitine doses and two ketotifen doses lowered MDA and increased TAC. Treating with ketotifen at 4 mg/kg was ineffective; however, when combined with l-carnitine (25 mg/kg), it provided antioxidant benefits. Ketotifen and l-carnitine, by affecting the oxidative stress pathway, reduce the symptoms of morphine dependence and act as potential pharmacological treatments for this condition.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":"36 7","pages":"509-516"},"PeriodicalIF":1.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Behavioural PharmacologyPub Date : 2025-10-01Epub Date: 2025-08-25DOI: 10.1097/FBP.0000000000000851
Mengjing Chen, Qiuju Lyu, Lina Huang, Yeliang Lou, Lingfeng Wang
{"title":"Gut-brain axis and depression: focus on the amino acid and short-chain fatty acid metabolism.","authors":"Mengjing Chen, Qiuju Lyu, Lina Huang, Yeliang Lou, Lingfeng Wang","doi":"10.1097/FBP.0000000000000851","DOIUrl":"10.1097/FBP.0000000000000851","url":null,"abstract":"<p><p>Depression, a major psychiatric disorder with profound societal impact, remains incompletely understood in its etiology. Identifying novel pathogenic pathways is therefore essential. The gut microbiota ('second brain') critically regulates bidirectional gut-brain axis (GBA) communication with the central nervous system. Dysbiosis correlates strongly with depression, positioning microbiota restoration as a promising therapeutic strategy. Critically, gut microbial metabolic processes - particularly involving amino acids and short-chain fatty acids (SCFAs) - have emerged as key contributors to depression pathogenesis; however, depression-specific alterations in gut microbiota and their metabolic signatures are inadequately characterized, and the molecular mechanisms linking microbial metabolites to depression require further elucidation. This review synthesizes recent advances on GBA-mediated depression pathogenesis, with emphasis on gut dysbiosis-induced disruptions in amino acid and SCFA metabolism, and delineates their mechanistic links to depressive pathophysiology.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":"36 7","pages":"439-453"},"PeriodicalIF":1.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Behavioural PharmacologyPub Date : 2025-10-01Epub Date: 2025-08-25DOI: 10.1097/FBP.0000000000000839
Ashish Jain, Neha Dhir, Amit Raj Sharma, Anupam Raja, Praisy K Prabha, Alka Bhatia, Bikash Medhi, Ajay Prakash
{"title":"Valproic acid triggers a sex-independent autism-like deficits, gut-brain axis, and neurodegenerative changes in the autism model of Wistar rats.","authors":"Ashish Jain, Neha Dhir, Amit Raj Sharma, Anupam Raja, Praisy K Prabha, Alka Bhatia, Bikash Medhi, Ajay Prakash","doi":"10.1097/FBP.0000000000000839","DOIUrl":"10.1097/FBP.0000000000000839","url":null,"abstract":"<p><p>Autism spectrum disorder (ASD) is a complex neurodevelopmental condition characterized by deficits in social interaction, communication, restricted interests, and repetitive behaviors. Its higher prevalence in males underscores the importance of understanding potential sex-specific differences. Prenatal exposure to valproic acid (VPA) is a widely used preclinical model to induce ASD-like traits in rodents; however, few studies have systematically compared neurobehavioral outcomes in both sexes. Here, we aimed to investigate sex-specific variations in developmental, behavioral, and physiological parameters in Wistar rat offspring prenatally exposed to VPA. Pregnant rats received a single intraperitoneal injection of VPA (600 mg/kg) or saline on gestational day (GD) 12.5, and offspring were assigned to four groups: control males, control females, VPA males, and females (n = 9 per group). VPA-exposed rats of both sexes exhibited autism-like behaviors, including heightened anxiety, increased exploratory activity, repetitive behaviors, social deficits, spatial and recognition memory impairments, and depressive-like traits. Physiological assessments revealed altered gastrointestinal (GIT) motility, increased brain edema, impaired blood-brain barrier (BBB) function, and neuronal injury with no sex-based difference in estrogen β (ERβ/ESR2) mRNA expression. These findings demonstrate that in utero exposure to VPA induces autism-like behaviors, developmental abnormalities, and neurodegenerative changes in both rat sexes, emphasizing the importance of including females in preclinical ASD research.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":"36 7","pages":"454-470"},"PeriodicalIF":1.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jianbiao Xu, Jianhua Bai, Junfeng Wang, Yun Jin, Wei Chang, Lanjiang Li, Lei Zou
{"title":"Efficacy and safety of Qudu Huiyuan Pills in the treatment of opioid withdrawal syndrome: a randomized, double-blind, placebo-controlled clinical trial.","authors":"Jianbiao Xu, Jianhua Bai, Junfeng Wang, Yun Jin, Wei Chang, Lanjiang Li, Lei Zou","doi":"10.1097/FBP.0000000000000846","DOIUrl":"https://doi.org/10.1097/FBP.0000000000000846","url":null,"abstract":"<p><p>This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of Qudu Huiyuan Pills (QHP), a novel Traditional Chinese Medicine (TCM) formulation, in treating opioid withdrawal syndrome (OWS). The study involved 124 adults (aged 18-65 years) diagnosed with opioid dependence and the TCM syndrome of Qi-blood deficiency and toxin-stasis. Participants were randomized to receive either QHP (n = 63) or a placebo (n = 61) at a dosage of 10 g three times daily for 5 months. Primary outcomes included changes in major and minor TCM symptom scores. Secondary outcomes encompassed neurobiological markers, liver function tests, and safety assessments. QHP treatment resulted in a statistically significant reduction in both major and minor TCM symptom scores compared with baseline and the placebo group (P < 0.01 for both). The safety profile of QHP was favorable; reported adverse events were predominantly mild and transient gastrointestinal discomfort. Notably, QHP treatment was associated with improved liver function markers, suggesting potential hepatoprotective effects. No significant between-group differences were observed in the assessed neurotransmitter or cytokine levels at the study endpoint. In conclusion, QHP appears to be an effective and safe therapeutic option for individuals with OWS, particularly in alleviating the constellation of symptoms defined by TCM. Further research is warranted to explore its long-term efficacy and underlying mechanisms of action.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145184627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Saadet Inan, Paige Morris, Scott M Rawls, Stephanie Daws
{"title":"Psilocybin inhibits formalin-induced nociception through 5-hydroxytryptamine 2A receptor in rats.","authors":"Saadet Inan, Paige Morris, Scott M Rawls, Stephanie Daws","doi":"10.1097/FBP.0000000000000856","DOIUrl":"https://doi.org/10.1097/FBP.0000000000000856","url":null,"abstract":"<p><p>Psilocybin is found in a family of mushrooms commonly known as Psilocybe. We aimed to study the antinociceptive efficacy of psilocybin using formalin-induced noxious stimuli, a model that comprises both acute and persistent pain in rats. Adult male Sprague-Dawley rats were used. Psilocybin (0.1, 0.3, and 1 mg/kg, IP) or vehicle was administered, and 6 h later, formalin (5%, 50 µL, subcutaneous) was injected into the hindpaw, and the number of flinches and time spent for licking were recorded for 0-10 and 20-60 min for acute and tonic phases, respectively. Another set of rats was used to examine if the antinociceptive effect of psilocybin is via 5-hydroxytryptamine2a receptor (5-HT2AR). For this aim, rats were pretreated with volinanserin (0.1 mg/kg, highly selective 5-HT2AR antagonist) or vehicle 30 min before psilocybin (0.3 mg/kg). Six hours later, formalin was injected, and the number of flinches and time spent for licking were recorded. Psilocybin (0.1 and 0.3 mg/kg) significantly reduced flinching and licking behaviors in both acute and late pain phases and pretreatment with volinanserin blocked the antinociceptive effect of psilocybin. Our results suggest that psilocybin produces an analgesic effect for acute and tonic inflammatory pain, at least in part, by activating 5-HT2AR.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145184442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}